Clinical Trials Logo

Pheochromocytoma clinical trials

View clinical trials related to Pheochromocytoma.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06330558 Completed - Adrenal Tumor Clinical Trials

Side-specific Factors for Conversion in Adrenalectomy for Pheochromocytoma.

Start date: September 1, 2016
Phase:
Study type: Observational

Context: Adrenalectomy for pheochromocytoma (PHEO) poses difficulties due to the elevated chance of conversion. The objective of this study was to conduct a comparative analysis of the occurrence and determinants of conversion in left-sided abdominal laparoscopic adrenalectomy (LLA) and right-sided abdominal laparoscopic adrenalectomy (RLA). Methods: A retrospective analysis was conducted to include a total of 271 patients diagnosed with PHEO. These patients were separated into two groups: LRA (N=121) and LLA (N=150). The study period spanned from September 2016 to September 2023.

NCT ID: NCT06064370 Completed - adrenalDisease Clinical Trials

Intraoperative Hemodynamic Instability in Adrenalectomy for Pheochromocytoma.

Start date: September 1, 2016
Phase:
Study type: Observational

The performance of adrenalectomy for pheochromocytoma (PHEO) presents significant challenges due to the presence of elevated intraoperative hemodynamic instability (HI) and conversion risk. The objective of this study was to conduct a comparative analysis of the occurrence and determinants of perioperative hypotension (HI) and conversion in left-sided (LLA) and right-sided (RLA) transabdominal laparoscopic adrenalectomy (TLA).

NCT ID: NCT06037135 Completed - Pheochromocytoma Clinical Trials

Dexmedetomidine Infusion During Laparoscopic Adrenalectomy

Start date: December 3, 2012
Phase: N/A
Study type: Interventional

The investigators planned this study to investigate the effects of dexmedetomidine administration on intraoperative hemodynamic stability in patients with pheochromocytoma.

NCT ID: NCT05858177 Completed - Clinical trials for Paraganglioma, Malignant

The Efficacy and Safety of Temozolomide in Patients With MPPGL

MPPGL
Start date: October 1, 2019
Phase: Phase 2
Study type: Interventional

Metastatic pheochromocytoma / paraganglioma (MPP) are rare while the prognosis was poor. Temozolomide (TMZ) is a novel oral alkylation chemotherapeutic agent. TMZ has been recommended in National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2019 for treating MPP patients.However, studies investigating TMZ efficacy in MPP patients are extremely limited. The largest study involved only 15 patients till date. The safety and efficacy of TMZ treatment in MPP patients need to be verified in larger studies.

NCT ID: NCT05803330 Completed - Hemodynamic Clinical Trials

Study of Alpha-blockers Alone During Preoperative Preparation in Patients With Pheochromocytoma

Start date: February 20, 2014
Phase: N/A
Study type: Interventional

Study of the relationship between hemodynamic stability and preoperative intravenous rehydration in patients with pheochromocytoma

NCT ID: NCT05102058 Completed - Clinical trials for Hemodynamic Instability

Magnesium and Dexmedetomidine in Pheochromocytoma

Start date: January 1, 2011
Phase:
Study type: Observational

Anesthesia management of pheochromocytoma excision surgery is associated with severe hemodynamic fluctuations.The objective of this study was to compare the hypertensive episodes requiring sodium nitroprusside administration between the group treated with magnesium-dexmedetomidine and conventional group in pheochromocytoma.

NCT ID: NCT05082311 Completed - Pheochromocytoma Clinical Trials

Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma

PheoCard
Start date: January 19, 2019
Phase:
Study type: Observational [Patient Registry]

PHEOCHROMOCYTOMA (PCC)/ PARAGANGLIOMA are catecholamine secreting tumors with varied manifestations. Besides hypertension, PCC patients may have subclinical to overt cardiac and vascular dysfunction, which are important to recognize to minimize perioperative morbidity and mortality. Cardiovascular (CV) dysfunction can be in the form of hypertension, left ventricular (LV) hypertrophy, heart failure, cardiomyopathy, dysrhythmias, angina and Myocardial infarction. Literature search revealed a few retrospective and a few prospective studies, including one prospective follow up study conducted at SGPGIMS to document CV changes in PCC. Our institutional study was the first to document the nature and extent of CV dysfunction and cardiomyopathy and their reversal after surgical cure. The studies revealed that PCC patients had significantly higher LV mass index, higher LV diastolic dysfunction, subclinical impaired LV systolic function. Earlier studies postulated apparent improvement in various cardiac indices even with selective α-blockade and continued after surgical cure, with near normalization at 3 -6 months postoperatively. Detailed cardiac and vascular evaluation in PCC patients can be of help in preoperative optimization of cardiac risk and may provide prognostic information The literature on PCC-mediated CV dysfunction and catecholamine cardiomyopathy is largely limited to case reports and retrospective studies, with few reports of their reversal after curative PCC operations. Whether the duration of disease influence the function of heart was not apparently addressed in earlier trials. Trials that established the differences in the degree of cardiac dysfunction between normotensive and hypertensive PCC patients involved smaller proportion of study subjects. Sub clinical changes in endomyocardium was presumed but not objectively assessed and hence its reversal after surgical cure is uncertain. The aim of this research is to study the cardiac and vascular changes in Pheochromocytoma/ Paraganglioma patients and their reversal following curative surgery

NCT ID: NCT04566406 Completed - Hypertension Clinical Trials

Pheochromocytoma and Hemodynamic Instability

Start date: January 2003
Phase:
Study type: Observational

The aims of our study were to define perioperative HI during laparoscopic adrenalectomy for pheochromocytoma, assess the incidence of perioperative HI, and identify predictive factors of perioperative HI in our group of patients.

NCT ID: NCT04557072 Completed - Pheochromocytoma Clinical Trials

Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysis

Start date: August 1, 2020
Phase:
Study type: Observational

Our aim was to systematically evaluate the current data on the efficacy of pretreatment with either selective or nonselective alpha-blockade on the hemodynamic instability and morbidity during pheochromocytoma resection.

NCT ID: NCT04320589 Completed - Pheochromocytoma Clinical Trials

the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma

Start date: June 30, 2019
Phase: Phase 2
Study type: Interventional

Pheochromocytoma (pheo) is a catecholamine secreting tumor arising from chromaffin cells of the adrenal medulla in 90% of cases & in 10% is extra-adrenal arising from the sympathetic chain. It is malignant in 10% of cases, bilateral in 10% of patients & 10% of all pheo are inherited (Familial Pheo) as autosomal dominant either alone or as a part of multiple endocrine neoplasia (MEN) syndrome.In this prospective work, the investigators will try to compare the peri-operative hemodynamic course of Dexmedetomidine & magnesium sulphate (MgSo₄) infused patients with the traditional anesthetic technique (α₁ & β-adrenergic blockers plus vasodilators) during open surgical resection of Pheo. The investigators are aiming to check the safety & efficacy of the recommended technique on the peri-operative hemodynamic stability & controlling the hypertensive crisis during tumor manipulation.